Dirk P Slaker

Patient-driven Medical Director offering 20-year history managing hospital, provider and payer functions to optimize operations and foster superior organization-wide service delivery. Expert in patient care and business administration with success designing effective patient care and business models. Focused on continuous quality improvement and leadership development.

Original Papers

Edelstein G, Levitt RG, Slaker DP, Murphy WA.  Computed Tomography of Tietze Syndrome.  J Comput Assist Tomogr, February 1978; 8:20-23.

Slaker DP, Edelstein G, Gilula LA.  Roentgen Rounds #71. Orthapaedic Review, Vol.XIII, No. 6, June 1984.

Edelstein G, Levitt RG, Slaker DP, Murphy WA. CT Observations of Rib Abnormalities: Spectrum of Findings. J Comput Assist Romogr, Jan-Feb 1985; 9:65-72.

Slaker DP, Bonovsky HL.  Hemochromatosis: The Forgotten Disease. Emory University Journal of Medicine, October 1989; 1:480-92.

Bonkovsky HL, Slaker DP, Bills EB, Wolf DC.  Usefulness and Limitations of Laboratory and Hepatic Imaging Studies in Iron- Storage Disease.  Gastroenterology, 1990; 98-1079-1091.

Stengele U, Baumgartner BR, Chezmer JP, Slaker DP.  Biliary Lithotripsy versus Cholecystectomy: A cost-Utility Analysis.  Journal of Lithotripsy and Stone Disease, 1991;Vol. 3, No. 2:133-139.

Bonkovsky HL, Fiellin DA, Smith GA, Slaker DP, Simon D, Galambos JT. A Randomized Controlled Trial of Treatment Hepatitis with Parenteral Nutrition and Oxandrolone 1. Short Term Effects on Liver Functions. The American Journal of Gastroenterology, Vol. 86, No. 9, 1991:1200-1208.

Bonkovsky HL, Singh RH, Jafri IH, Fiellin DA, Smith GS, Simon D, Costsonis G, Slaker DP.  A Randomized Controlled Trial of Treatment of Alcoholic Hepatitis with Parenteral Nutrition and Oxandrolone II. Short Term Effects on Nitrogen Metabolism, Metabolic Balance, and Nutrition. The American Journal of Gastroenterology, Vol. 86, No. 9,1991:1209-1218.

Abstracts

Bonkovsky HL, Fiellin D, Smith G, Slaker DP, Simon D, Galambos JT. Treatment of Alcoholic Hepatitis with Parenteral Nutrition and Oxandrolone; A Randomized Controlled Trial I. Short-term Effects on Liver Function. Hepatology, Vol. 12, No. 4:870. 1990.

Bonkovsky HL, Jafri I, Singh R, Cotsonis G, Slaker DP.  Treatment of Alcoholic Hepatitis with Parenteral Nutrition and Oxandrolone: A Randomized Controlled Trial II. Effects on Nitrogen Metabolism. Hepatology, Vol. 12, No. 4:978. 1990.

Zeuzem S, Mannis M, Rustigi V, Aurora S, Smith C, Shiffman M, Reddy R, Reindollar R, Slaker D, Ral R, Keeffee E and the International Interferon Aalfacon-1 Study Group. Daily Interferon Alfacon-1(infergen) Therapy:  Interim Results from an Ongoing International Clinical Trial to Compare Daily Interferon Alfacon-1 Therapy (9mcg/48 weeks) to Standard Regiments of Thrice Weekly (TIW) Interferon Alfacon-1 (9mcg) for Treatment of Chronic Hepatitis C Virus.Journal of Hepatology Vol. 34, Supplement 1:177, 2001

Kugelmas M, Levinson MJ, Stribling RJ, Slaker DP, Fegel D, Shdlofsy S, Trouillot TE.  Treatment of Rebetron-Resistant Chronic Hepatitis C with PEG-Intron and Ribavirin: An interim Analysis. Submitted to AASLD, November 2001.

Scientific Presentations

Slaker DP, Bills EB, Mellen BG, Wolf DC, Bernardino ME, Bonkovsky HL. The diagnosis of hemochromatosis: Is the live biopsy passé? Presented at the Annual Meeting of the American Gastroenterology Associations.  Chicago, IL. May 1987.

Chezmar JL, Slaker DP, Nelson RC, Bills E, Malko J, Bernardino ME. Hepatic Iron overload: diagnosis and quantification of MR imaging.  Presented to the Annual Meeting of the American Roentgen Ray Society.  San Francisco, CA. May 1988.

Slaker DP, Mellen B, Wolf D, Bonkovosky H. Evaluation of iron storage disease: Usefulness and limitations of laboratory and hepatic imaging studies.  Presented at the Annual Meeting of the American Association for the Study of Liver Disease.  Chicago, IL. November 1988.

Research

A. Principle Investigator or Co-investigator

Amgen Protocol CIFN-970281: Randomized, non-blinded, multi-center, parallel group trial to compare the efficacy of 9 mcg interferon alfacon-1 administered subcutaneously 3 X per week for 28 weeks or 72 weeks, or once daily for 48 weeks in patient with  chronic hepatitis C infection previously untreated with interferon.

Glaxo Protocol S3B30012: A six week trial of alosetron hydrochloride twice daily as empiric therapy in female subjects with symptoms of non-constipated irritable bowel syndrome.

A randomized, open label multi-center, efficacy and safety study of Pegasys plus amantadine and Pegasys plus amantadine plus ribavirin, and comparison of Rebetron with Pegasys plus Cellcept, as initial treatment, an initial treatment in patients with chronic HCV infection.

Daily Infergen therapy for patients with chronic hepatitis C virus who have failed previous treatment. Amgen Protocol CIFN-2000103: Randomized open label pilot study to Determine the efficacy of 9 mcg versus 15 mcg of Infergen when given daily for chronic hepatitis C in African-American subjects who are naive to previous therapy.

Comparison of PEG-IFN vs. Intron A for treatment of adult subjects with chronic hepatitis C not previously treated with interferon; dose finding study. A prospective, randomized, multi-center, open label, comparative safety study of Pegasys vs Pegasys plus ribavirin treatment vs a twelve week delay in patients with chronic hepatitis C.

211-03-00 Treatment of chronic hepatitis C previously not responsive to Interferon with/without Ribavirin with PEG-Interon and Rebetol.

244-11-00 Comparison of PEG Interferon alfa-2b plus ribavirin given as a fixed dose or on a weight optimized basis for treatment of chronic hepatitis C in previously untreated adult subjects BB_IND#-9243.

A pilot clinical study to assess the use of extracorporeal hyperthermia in patients previously unresponsive to pegylated interferon and ribavirin: A ten patient Phase I clinical investigation